| 10/07/2026 10:07 AM | Neurogene (1404644) Subject PRUDENTIAL FINANCIAL INC (1137774) Filed by | Form SCHEDULE 13G | |
| 10/06/2026 12:49 PM | JENNISON ASSOCIATES LLC (53417) Filed by Neurogene (1404644) Subject | Form SCHEDULE 13G | |
| 10/02/2026 1:49 PM | McMinn Rachel (1606302) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 3:15 PM | Neurogene (1404644) Subject Trails Edge Capital Partners, LP (2077247) Filed by | Form SCHEDULE 13G/A | |
| 08/14/2026 5:05 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Neurogene (1404644) Subject | Form SCHEDULE 13G | |
| 08/11/2026 3:57 PM | Neurogene (1404644) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/11/2026 6:32 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/07/2026 8:08 PM | Cvijic Christine Mikail (1543663) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 5:42 PM | Cvijic Christine Mikail (1543663) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2026 3:19 PM | Neurogene (1404644) Filer | Form 424B5 | |
| 06/29/2026 7:00 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for NGNE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/16/2026 4:30 PM | Neurogene (1404644) Issuer Woods Keith (1996804) Reporting | Form 3/A | |
| 06/16/2026 4:31 PM | Neurogene (1404644) Issuer Woods Keith (1996804) Reporting | Form 4/A | |
| 06/16/2026 4:32 PM | Neurogene (1404644) Issuer Woods Keith (1996804) Reporting | Form 4/A | |
| 06/16/2026 4:32 PM | Neurogene (1404644) Issuer Woods Keith (1996804) Reporting | Form 4/A | |
| 06/08/2026 6:32 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/04/2026 3:41 PM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/12/2026 3:04 PM | Neurogene (1404644) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/12/2026 3:06 PM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/08/2026 10:51 AM | Cvijic Christine Mikail (1543663) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 11:35 AM | Neurogene (1404644) Issuer Shafer Christina (1934412) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/20/2026 5:26 PM | Neurogene (1404644) Issuer Shafer Christina (1934412) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/20/2026 6:32 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/16/2026 3:22 PM | Neurogene (1404644) Filer | Form ARS | |
| 04/16/2026 3:15 PM | Neurogene (1404644) Filer | Form DEF 14A | |
| 04/16/2026 3:15 PM | Neurogene (1404644) Filer | Form DEFA14A | |
| 03/24/2026 3:16 PM | Neurogene (1404644) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/24/2026 6:31 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/17/2026 5:01 PM | Cvijic Christine Mikail (1543663) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/17/2026 5:01 PM | Cobb Stuart (1994301) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/13/2026 3:20 PM | Cobb Stuart (1994301) Reporting Neurogene (1404644) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/26/2026 3:02 PM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/24/2026 5:40 PM | Neurogene (1404644) Issuer Woods Keith (1996804) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:40 PM | Freedland Cory S. (1832569) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:40 PM | Neurogene (1404644) Issuer Noonberg Sarah B. (1706301) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:41 PM | BAFFI ROBERT (1274826) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:48 PM | Neurogene (1404644) Issuer PALEKAR ROHAN (1423327) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:48 PM | McMinn Rachel (1606302) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:49 PM | Cvijic Christine Mikail (1543663) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:49 PM | Jordan Julie (1968554) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/24/2026 5:49 PM | Cobb Stuart (1994301) Reporting Neurogene (1404644) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
The AI Infrastructure Rush Is ON — Watch VDTA (Ad) Vertical Data Inc (OTCQB: VDTA) is building the layers beneath the AI boom - GPU hardware and financing, managed infrastructure, high-density data centers and edge computing.
The company points to an AI infrastructure market that could top 800 billion dollars by 2030, with a 20 MW Chicago data center targeting revenue in Q2 2027. A non-binding collaboration with Quantum eMotion is exploring quantum-security integration into GPU clusters, with an initial pilot targeted for 2026. See why VDTA is one AI infrastructure name worth watching now |
| 01/12/2026 6:00 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/15/2025 5:00 PM | Neurogene (1404644) Subject Trails Edge Capital Partners, LP (2077247) Filed by | Form SCHEDULE 13G | |
| 11/13/2025 4:11 PM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/12/2025 4:11 PM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/06/2025 6:31 AM | Neurogene (1404644) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |